Top Markets
#1 Decred Decred +10.19%
#2 Wibx Wibx +9.06%
#3 Status Status +7.37%
#4 aelf aelf +5.49%
#5 SkyAI SkyAI +4.75%
#6 MarsCoin MarsCoin +4.32%
#7 Rei Rei +4.03%
#8 Robinhood Wrapped ETH (Robinhood Chain) Robinhood Wrapped ETH (Robinhood Chain) +3.86%
#9 TRIA TRIA +3.71%
#10 Humanity Humanity +3.23%
Coin of the day
Decred Decred
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc.

INTI
Classement en actions #30838
Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida,... Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work involves advancing SUBA-Itraconazole, an oral variant of the drug itraconazole, for therapeutic applications in prostate and lung cancers. Furthermore, Inhibitor Therapeutics, Inc. has successfully completed a positive Phase 2b clinical trial for SUBA-Itraconazole in the management of basal cell carcinoma nevus syndrome. The organization was previously known as HedgePath Pharmaceuticals, Inc. until its name was officially changed in August 2019.
Prix de l'action
$0.089
Dernière synchronisation: 2026-08-17
Capitalisation boursière
$15.36M
Changement (1 jour)
50.59%
Changement (1 an)
72.65%
Pays
US
Échange Inhibitor Therapeutics, Inc. (INTI)

Catégorie

Healthcare
Revenus pour Inhibitor Therapeutics, Inc. (INTI)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de Inhibitor Therapeutics, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Inhibitor Therapeutics, Inc. de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE